[go: up one dir, main page]

AR044665A1 - Derivados benzoimidazolicos, composiciones que los contienen, su preparacion y usos de los mismos - Google Patents

Derivados benzoimidazolicos, composiciones que los contienen, su preparacion y usos de los mismos

Info

Publication number
AR044665A1
AR044665A1 ARP040102016A ARP040102016A AR044665A1 AR 044665 A1 AR044665 A1 AR 044665A1 AR P040102016 A ARP040102016 A AR P040102016A AR P040102016 A ARP040102016 A AR P040102016A AR 044665 A1 AR044665 A1 AR 044665A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
heterocyclyl
cycloalkenyl
alkynyl
Prior art date
Application number
ARP040102016A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29212433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR044665(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR044665A1 publication Critical patent/AR044665A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a derivados benzoimidazólicos, composiciones farmacéuticas que incluyen los compuestos. Estos son usados en terapia, en especial en el manejo del dolor. Reivindicación 1: Un compuesto de fórmula (1) o su sal aceptable para uso farmacéutico: en el cual Z se selecciona de O= y S=; R1 se selecciona de alquilo C1-10, alquenilo C2-10, alquinilo C2-10, R5R6N-alquilo C1-6, R5O-alquilo C1-6, R5C(=O)N(-R6)-alquilo C1-6, R5R6NS(=O)2-alquilo C1-6, R5CS(=O)2N(-R6)-alquilo C1-6, R5R6NC(=O)N(-R7)-alquilo C1-6, R5R6NS(=O)2N(R7)-alquilo C1-6, aril-C6-10-alquilo C1-6, aril-C6-10-C(=O)-alquilo C1-6, cicloalquil-C3-10-alquilo C1-6, cicloalquenil-C4-8-alquilo C1-6, heterociclil-C3-6-alquilo C1-6, heterociclil-C3-6-C(=O)-alquilo C1-6, hidrocarbilamino C1-10, R5R6N-, R5O-, R5C(=O)N(-R6)-, R5R6NS(=O)2-, R5CS(=O)2N(-R6)-, R5R6NC(=O)N(-R7)-, R5R6NS(=O)2N(R7)-, arilo C6-10, aril-C6-10-C(=O)-, cicloalquilo C3-10, cicloalquenilo C4-8, heterociclilo C3-6 y heterociclil-C3-6-C(=O)-, donde dicho alquilo C1-10, alquenilo C2-10, alquinilo C2-10, aril-C6-10-alquilo C1-6, aril-C6-10-C(=O)-alquilo C1-6, cicloalquil-C3-10-alquilo C1-6, cicloalquenil-C4-8-alquilo C1-6, heterociclil-C3-6-alquilo C1-6, heterociclil-C3-6-C(=O)-alquilo C1-6, hidrocarbilamino C1-10, arilo C6-10, aril-C6-10-C(=O)-, cicloalquilo C3-10, cicloalquenilo C4-8, heterociclilo C3-6 o heterociclil-C3-6-C(=O)- usado para definir R1 está sustituido opcionalmente con uno o más grupos seleccionados de carboxi, halógeno, ciano, nitro, metoxi, etoxi, metilo, etilo, hidroxi y -NR5R6; R2 se selecciona del grupo conformado por alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-8, cicloalquil-C3-8-alquilo C1-6, cicloalquenil-C4-8-alquilo C1-6, heterocicloalquil-C3-6-alquilo C1-6, cicloalquenilo C4-8, R5R6N-, heteroarilo C3-5, arilo C6-10 y heterocicloalquilo C3-6, donde dicho alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-8, cicloalquil-C3-8-alquilo C1-6, cicloalquenil-C4-8-alquilo C1-6, heterocicloalquil-C3-6-alquilo C1-6, cicloalquenilo C4-8, heteroarilo C3-5, arilo C6-10 o heterocicloalquilo C3-6 usado para definir R2 está sustituido opcionalmente con uno o más grupos seleccionados de halógeno, ciano, nitro, metoxi, etoxi, metilo, etilo, hidroxi y -NR5R6; donde R5, R6 y R7 se seleccionan independientemente de -H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, y un grupo de C1-6 divalente que junto con otro divalente R5, R6 o R7 forma una porción de un anillo; y R3 y R4 se seleccionan independientemente de -H, -OH, amino, R8 y -O-R8, donde R8 se selecciona independientemente de alquilo C1-6, alquenilo C2-6, alquinilo C2-6 y un grupo de C1-6 divalente que junto con otro divalente R8 forma una porción de un anillo, donde R3 y R4 no son -H al mismo tiempo y donde dicho alquilo C1-6, alquenilo C2-6, alquinilo C2-6 o grupo de C1-6 divalente al definir R8 está sustituido opcionalmente con uno o más grupos seleccionados de carboxi, halógeno, ciano, nitro, metoxi, etoxi, hidroxi, carboxi y -NR5R6; o R3 y R4 junto con el N unido a los mismos forman una porción de un anillo de 5 o 6 miembros, donde dicho anillo está sustituido opcionalmente con uno o más grupos seleccionados de carboxi, halógeno, ciano, nitro, metoxi, etoxi, hidroxi, carboxi y NR5R6.
ARP040102016A 2003-06-10 2004-06-10 Derivados benzoimidazolicos, composiciones que los contienen, su preparacion y usos de los mismos AR044665A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301699A SE0301699D0 (sv) 2003-06-10 2003-06-10 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Publications (1)

Publication Number Publication Date
AR044665A1 true AR044665A1 (es) 2005-09-21

Family

ID=29212433

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102016A AR044665A1 (es) 2003-06-10 2004-06-10 Derivados benzoimidazolicos, composiciones que los contienen, su preparacion y usos de los mismos

Country Status (24)

Country Link
US (1) US7517898B2 (es)
EP (1) EP1636193A1 (es)
JP (1) JP2006527247A (es)
KR (1) KR20060017863A (es)
CN (2) CN1805940A (es)
AR (1) AR044665A1 (es)
AU (1) AU2004245296B2 (es)
BR (1) BRPI0411226A (es)
CA (1) CA2528924A1 (es)
CO (1) CO5660261A2 (es)
IL (1) IL172027A0 (es)
IS (1) IS8220A (es)
MX (1) MXPA05013050A (es)
MY (1) MY139676A (es)
NO (1) NO20060146L (es)
NZ (1) NZ543632A (es)
RU (1) RU2329254C2 (es)
SA (1) SA04250161B1 (es)
SE (1) SE0301699D0 (es)
TW (1) TW200504030A (es)
UA (1) UA83832C2 (es)
UY (1) UY28357A1 (es)
WO (1) WO2004108688A1 (es)
ZA (1) ZA200509869B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE545644T1 (de) 2004-09-24 2012-03-15 Astrazeneca Ab Benzimidazolderivate, diese enthaltende zusammensetzungen, herstellung davon und anwendungen davon i
EP1912930A4 (en) * 2005-07-29 2010-04-14 Astrazeneca Ab PROCESS FOR PREPARING GEMINAL ((DIFLUORCYCLOALKYL) METHYL) AMINE
BRPI0707979A2 (pt) * 2006-02-20 2011-05-17 Astellas Pharma Cin derivado de amida ou sal deste
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) * 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
TW200808772A (en) * 2006-06-13 2008-02-16 Astrazeneca Ab Therapeutic compounds
US20080139846A1 (en) * 2006-09-01 2008-06-12 Astrazeneca Ab New Process 298
WO2008153701A1 (en) * 2007-05-24 2008-12-18 Schering Corporation Compounds for inhibiting ksp kinesin activity
CA2709883A1 (en) * 2007-12-19 2009-06-25 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
US20110086853A1 (en) * 2009-10-08 2011-04-14 William Brown Therapeutic Compounds
RU2414899C1 (ru) * 2009-12-29 2011-03-27 Аверин Константин Михайлович Средства для лечения рассеянного склероза
US20130196990A1 (en) * 2010-10-06 2013-08-01 Junya Qu Benzimidazole Derivatives As PI3 Kinase Inhibitors
PT2897939T (pt) 2012-09-21 2017-05-04 Sanofi Sa Derivados de amida do ácido benzoimidazol-carboxílico para tratamento de doenças metabólicas ou cardiovasculares
BR112017019453A2 (pt) 2015-03-13 2018-05-15 Forma Therapeutics Inc compostos e composições de alfa-cinamida como inibidores de hdac8

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4201554A1 (de) * 1992-01-22 1993-07-29 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9121776D0 (en) * 1991-10-14 1991-11-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives and process for preparation thereof
JP3295277B2 (ja) * 1994-06-01 2002-06-24 呉羽化学工業株式会社 抗腎疾患剤及びベンズイミダゾール誘導体
WO1997024334A1 (en) * 1995-12-28 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
US6348032B1 (en) * 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
JP2001247550A (ja) * 1999-12-27 2001-09-11 Japan Tobacco Inc 縮合環化合物及びその医薬用途
PA8535601A1 (es) * 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
SE0101387D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab Novel compounds
US7196095B2 (en) * 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
TWI231757B (en) * 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
AU2002347022A1 (en) 2001-12-20 2003-07-09 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
SE0203070D0 (en) * 2002-10-16 2002-10-16 Astrazeneca Ab Novel compounds
SE0301698D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Also Published As

Publication number Publication date
SA04250161B1 (ar) 2009-04-18
WO2004108688A1 (en) 2004-12-16
MXPA05013050A (es) 2006-03-02
TW200504030A (en) 2005-02-01
NO20060146L (no) 2006-03-07
UY28357A1 (es) 2005-01-31
UA83832C2 (ru) 2008-08-26
IL172027A0 (en) 2011-08-01
SE0301699D0 (sv) 2003-06-10
IS8220A (is) 2006-01-04
ZA200509869B (en) 2006-11-29
NZ543632A (en) 2009-02-28
RU2005138371A (ru) 2006-07-27
CN1805940A (zh) 2006-07-19
KR20060017863A (ko) 2006-02-27
CO5660261A2 (es) 2006-07-31
AU2004245296B2 (en) 2008-05-22
RU2329254C2 (ru) 2008-07-20
CA2528924A1 (en) 2004-12-16
EP1636193A1 (en) 2006-03-22
JP2006527247A (ja) 2006-11-30
US7517898B2 (en) 2009-04-14
BRPI0411226A (pt) 2006-07-18
AU2004245296A1 (en) 2004-12-16
US20070060583A1 (en) 2007-03-15
MY139676A (en) 2009-10-30
CN101328151A (zh) 2008-12-24

Similar Documents

Publication Publication Date Title
AR044665A1 (es) Derivados benzoimidazolicos, composiciones que los contienen, su preparacion y usos de los mismos
AR044666A1 (es) Derivados benzoimidazolicos, composiciones que los contienen, su preparacion y usos de los mismos.
AR045819A1 (es) Derivados de benzimidazol composiciones que los contienen, preparacion de los mismos y usos de los mismos
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR044543A1 (es) Derivados de pirazolo-quinazolina, un procedimiento para su preparacion y su uso como inhibidor de quinasa
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
AR053699A1 (es) Derivados de tetrahidro-1h-pirido[4,3-b]indoles como ligandos de receptores cb1
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
AR077463A1 (es) Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias
AR059481A1 (es) Derivados de 1, 3-dihidro-imidazo[4, 5-c]piridin-2-ona como agonista del receptor tlr7, un metodo para su preparacion, intermediarios de sintesis de los mismos, una composicion farmaceutica que los comprende y su uso en la elaboracion de un medicamento para el tratamiento de infecciones viricas.
CL2011001924A1 (es) Compuestos derivados de aminotetralina, inhibidores de glyt1; composicion farmaceutica que lo comprende; compuestos intermediarios; y uso en el tratamiento de problemas neurologicos, psiquiatricos o dolor.
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
AR044011A1 (es) Antagonistas de mchr1 heterociclicos
AR035858A1 (es) Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3
AR044152A1 (es) Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
AR043508A1 (es) 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores
AR054214A1 (es) Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c.
AR060472A1 (es) Derivados de sulfonil-benzimidazoles moduladores o ligandos de receptores cb1, composiciones farmaceuticas que los contienen, metodo de preparacion y usos en terapia, particularmente para alivio del dolor.
AR041395A1 (es) Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
AR076731A1 (es) Prostamidas donadoras de oxido nitrico, uso de los mismos y composiciones farmaceuticas
AR049898A1 (es) Compuestos aminocarbonil fenilo sustituidos, composicion farmaceutica,uso y proceso para prepararlos
AR054481A1 (es) Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol
CL2021002621A1 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
AR045822A1 (es) Derivados de bencimidazol, composiciones que los contienen preparacion de los mismos y usos de los mismos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal